EDUCATION > Courses and Products > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > The Medical Management of BPH > Module 1: BPH Medical Management and Epidemiology of LUTS

Module 1: BPH Medical Management and Epidemiology of LUTS

Learning Objectives

After participating in this activity, participants should be able to:

  • describe the natural history, etiology, and pathophysiology of male LUTS and BPH

  • apply deepened understanding of the natural history of LUTS and BPH to the treatment of men in their practice

Faculty/Authors

Claus G. Roehrborn, MD
Professor and Chair, Department of Urology
UT Southwestern Medical Center at Dallas
Dallas, TX
Disclosures: Roehrborn, Claus: GlaxoSmithKline: Consultant/Advisor

Christopher Chapple, BSc, MD, FRCS (Urol)
Honorary Senior Lecturer of Urology, University of Sheffield
Consultant Urological Surgeon, Royal Hallamshire Hospital
Sheffield, United Kingdom
Disclosures: Chapple, Christopher R.: Pfizer: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Recordati: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Astellas: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Allergan: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; American Medical Systems: Consultant or Advisor,Scientific Study or Trial ; Lilly: Consultant or Advisor

BPH Medical Management

Claus G. Roehrborn, MD


A Paradigm Shift-epidemiology of LUTS, OAB and Contemporary Nomenclature

Christopher Chapple, BSc, MD, FRCS (Urol)


Etiology, Epidemiology Pathophysiology and Natural History of LUTS /BPH

Claus G. Roehrborn, MD

BPH and Medical Management


AUA. J Urol 2003;170:530–547;

AUA. Management of BPH (2010). http://www.auanet.org/;
Berry SJ et al. J Urol. 1984;132:474–479

Bulletin of the World Health Organization 2002;80:622-628

Castiñeiras Fernández J,et al. Actas Urol Esp 2010;34:24–34

de la Rosette JJ et al. Eur Urol 2001;40:256-263

Debruyne F et al. Eur Urol 1998;34:169-175

Iglehart J. N Engl J Med 2009;10.1056/NEJMp0901927

Jacobsen SJ et al. Arch Intern Med. 1995;155:477-48

Lepor H et al. N Engl J Med 1996;335:533–539

Madersbacher S et al. Eur Urol 2004;46:547–554

McConnell J et al. N Engl J Med 2003;349:2387-2398; 10. Kirby R et al. Urology 2003;61:119–126

Molero García JM et al. Criterios de derivación en hiperplasia prostática benigna para Atención Primaria, versión 2011. Aten Primaria 2011. doi:10.1016/j.aprim.2011.07.006

NICE clinical guideline 97 (2010). Available at: http://guidance.nice.org.uk/

Nickel J et al. Can Urol Assoc J 2010;4:310–316

Oelke M et al. Guidelines on the treatment of non-neurogenic male LUTS (2011) http://www.uroweb.org/

Roehrborn C et al. Eur Urol 2010;57:123−131

Roehrborn C et al. J Urol 2008;179:616−621

A Paradigm Shift-epidemiology of LUTS, OAB and contemporary nomenclature


Abrams et al. Urology 2003;61:37-49

Abrams P, et al. Neurol Urodyn 2002;21:167–178

Barry MJ et al 1995 3rd Int Cons BPH 21-36

Boyle P et al 2001 5th Int Cons BPH 19-68

Chapple CR & Roehrborn CG. Eur Urol 2006;49:651–659

Chatelain C, et al. 5th International Consultation on BPH 2000; Paris, France

de la Rosette JJ, et al. Neurourol Urodyn 2002;21:444–449

Hu TW et al. Incontinence. 2002:965-983

Jolleys et al. Br J Urol 1994;74:551-5

Lepor H et al. Rev Urol. 2004;6(Suppl9):S3-10

McConnell JD et al. N Engl J Med 2003;349:2387-98

Roehrborn CG. BJU Int 2006;97:734-41

Schatzl et al. Urology 2000;56:71-5

Van Dijk et al. BJU Int 2002;90:644-8

Van Kerrebroeck et al. BJU Int 2002;90(Suppl 3):11-5

Etiology, Epidemiology Pathophysiology and Natural History of LUTS /BPH


Bartsch G et al. In: Chatelain C et al, eds. Benign Prostatic Hyperplasia. Plymouth, UK: Health Publication Ltd; 2001:423-457

Berry SJ et al. J Urol. 1984;132:474-479

Bulletin of the World Health Organization 2002;80:622

Federman, D. D. N Engl J Med 2006;354:1507-1514

Gacci M, et al. Eur Urol. 2011;60(4):809-825

Iehlé et al. J Ster Biochem Mol Biol. 1999;68:189–195

Kristal et al. J Urol 2007; 177: 1395–400

Lee C et al. In: Chatelain C et al, eds. Benign Prostatic Hyperplasia. Plymouth, UK: Health Publication Ltd; 2001;79-106

Lepor H. Rev Urol. 2004;6(suppl 9):S3-S10

Parsons. J Urol 2007; 178: 395–401

Roehrborn CG (reviewer). Rev Urol. 2001;3:139-145

Roehrborn CG et al. Urology. 2002;60:434-441

Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Campbell's Urology. 8th ed. Philadelphia, PA: WB Saunders Co; 2002:1297-1336

Roehrborn CG. Int J Impot Res. 2008;20(suppl 3):S11-S18

Rohrmann. Epidemiology 2006; 17: 419–27

Rosen R, et al. Eur Urol. 2003;44:637-649

Thomas LN et al. Prostate. 2005;63:231–239

U.S. Census Bureau, 2000, 2001, Table PCT12; 2010 to 2050

U.S. Census Bureau, 2004

Wright et al. Endocrinology 1999; 140: 4509–15

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT